Targeting this subunit via specific PI3K inhibitors inhibits the insulin-dependent signaling, which in turn promotes glycogen breakdown in liver and inhibits glucose uptake in skeletal muscle and adipose tissues, resulting in hyperglycemia. The gene discussed is INS; the disease is Hyperglycemia.